Stocks of Eli Lilly and Novo plunged after Medicare excluded weight-loss drugs from coverage. Trump administration's new policies omitted them.
On Friday, the Trump administration announced finalized Medicare and Medicaid policies, causing Eli Lilly stock to drop. The exclusion of weight-loss drugs led to a dive in Eli Lilly and Novo stocks. The decision had significant effects on the market, with Eli Lilly experiencing a noticeable decline in stock value.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments